
Shixin Tao

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/362603/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Glycogen synthase kinase-3 inhibition attenuates fibroblast activation and development of fibrosis following renal ischemia/reperfusion in mice. DMM Disease Models and Mechanisms, 2015, 8, 931-40.	2.4	50
2	Specific deletion of glycogen synthase kinase-3β in the renal proximal tubule protects against acute nephrotoxic injury in mice. Kidney International, 2012, 82, 1000-1009.	5.2	47
3	Glycogen synthase kinase-3β promotes cyst expansion in polycystic kidney disease. Kidney International, 2015, 87, 1164-1175.	5.2	39
4	Targeting the vasopressin type-2 receptor for renal cell carcinoma therapy. Oncogene, 2020, 39, 1231-1245.	5.9	31
5	Glycogen synthase kinase 3α regulates urine concentrating mechanism in mice. American Journal of Physiology - Renal Physiology, 2015, 308, F650-F660.	2.7	26
6	Epithelial Vasopressin Type-2 Receptors Regulate Myofibroblasts by a YAP-CCN2–Dependent Mechanism in Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2020, 31, 1697-1710.	6.1	26
7	Glycogen synthase kinaseâ€3β inhibits tubular regeneration in acute kidney injury by a FoxM1â€dependent mechanism. FASEB Journal, 2020, 34, 13597-13608.	0.5	20
8	A cAMP and CREB-mediated feed-forward mechanism regulates GSK3 β in polycystic kidney disease. Journal of Molecular Cell Biology, 2016, 8, 464-476.	3.3	16
9	Glycogen Synthase Kinaseâ€3 Inhibition Reduces Renal Cystogenesis in Polycystic Kidney Disease. FASEB Journal, 2013, 27, 1115.20.	0.5	0